{
  "docId": "019de075-ab2a-73e5-980a-7d480707ba09",
  "docSlug": "340a1966b9939070959283ec1665bfbf",
  "documentTitle": "Kymera | Investor Presentation Deck | 60 slides",
  "authorId": "kymera",
  "authorName": "Kymera",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 45,
  "pageCount": 60,
  "prevPage": 44,
  "nextPage": 46,
  "slideType": "appendix_data",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 42,
  "notes": "Clinical trial safety data presentation.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-ab2a-73e5-980a-7d480707ba09/45",
  "deckHref": "/decks/019de075-ab2a-73e5-980a-7d480707ba09",
  "deckJsonHref": "/decks/019de075-ab2a-73e5-980a-7d480707ba09.json",
  "deckAnchorHref": "/decks/019de075-ab2a-73e5-980a-7d480707ba09#slide-45",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.9,
        "x": 0.05,
        "y": 0.85
      },
      "kind": "callout",
      "text": "Safety Summary: At the time of the data cut off (May 1, 2023), KT-333 was well tolerated, with no dose limiting toxicity observed and no serious adverse events considered related to KT-333.",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b4f5d961-efb0-4a5d-a302-7cd0f54b5bc1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.9,
        "x": 0.05,
        "y": 0.72
      },
      "kind": "disclaimer",
      "text": "(a) All Grade 1 and 2 events except the following: 1 patient with Gr. 3 abdominal pain and 1 patient with Gr. 3 fatigue that were not related to KT-333.\n(b) No Grade 4 or Grade 5 events.\n(c) At time of data cut off, DL4 had enrolled two patients and no AEs had been reported.\n(d) AEs related to KT-333 (n=1 each): Gr. 1: abdominal pain upper, LDH increase, and rash. Gr. 2: diarrhea; hypothyroidism; and squamous cell carcinoma (SCC) of the skin in CTCL patient with history of prior UVB treatment and recurrent skin SCCs considered possibly related.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f9918053-2d2c-4ff5-8421-3c021cddad72",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.14
      },
      "kind": "list",
      "text": "As of May 1, 2023, thirteen patients received a mean of five doses across four dose levels.\nTumor types enrolled: CTCL (n=2), PTCL (n=1), and solid tumors (n=10, including colorectal [2], appendiceal, anal, pancreatic, cholangiocarcinoma, peritoneal, endometrial, ovarian and head & neck)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "91496ae6-7b29-432b-9e40-4dd87644e2cb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.9,
        "x": 0.05,
        "y": 0.26
      },
      "kind": "table",
      "text": "Number of Patients with Adverse Event Occurring in ≥2 Patients (n, (%))",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c9e749dd-c622-4415-8b66-8bc1ebc2bc80",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.19,
        "x": 0.405,
        "y": 0.04
      },
      "kind": "title",
      "text": "Overall Safety",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "78e4c921-2487-44e0-b8f8-bb3524c66406",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 49,
      "from": 42,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "0814ecd6-3302-463c-8283-d9c36bf778b3",
      "evidence": "The deck presents the why, what, and how of STAT3 as a target",
      "position": 2,
      "objective": "Why is STAT3 a good target for oncology?",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.6,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}